Alexandra Popoff Buys Shares of Vivani Medical, Inc. $VANI

Editorial illustration for Vivani Medical, Inc. (VANI)

Key Points

  • Alexandra Popoff bought 36,516 shares of Vivani Medical, Inc. ($VANI) worth $44,549.52.
  • $VANI last traded around $1.20.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Alexandra Popoff, insider at Vivani Medical, Inc. ($VANI), bought 36,516 shares at an average price of $1.22, for a total transaction of $44,549.52. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Vivani Medical, Inc. Stock Down 15.8%

Shares of Vivani Medical, Inc. ($VANI) traded around $1.20 on Friday, down 15.8% for the day.

Last price$1.20
Market cap$125.38M
Forward P/E-3.97
Beta3.28
52-week low$0.92
52-week high$1.92
50-day MA$1.34
200-day MA$1.28
Current ratio3.25
Quick ratio3.09
Debt-to-equity0.94

Vivani Medical, Inc. Earnings

EPS (ttm)-$0.36
Revenue (ttm)
Net margin0%
Return on equity-220.41%
Next earningsNov 12, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$3.83
High target$4
Low target$3.50
Analysts covering3

About Vivani Medical, Inc.

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersAlameda, CA
CEODr. Adam Mendelsohn Ph.D.
Employees42

Get Vivani Medical, Inc. alerts

New 13F filings, insider trades, and analyst moves on $VANI, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.